the molecular landscape of disease.

Four platforms,
one architecture.

From focused clinical panels to full-proteome biobank studies — each platform is optimised for a different depth of biological question.

Focused clinical validation

Pre-defined panels of up to 45 verified and carefully selected biomarkers per panel, targeting cytokine signalling and inflammatory processes. Runs from 1 µL of plasma or serum.

The world's most published proteomics platform

Ninety-two proteins per panel across oncology, cardiovascular, inflammatory, and neurological themes — with over 4,000 peer-reviewed publications establishing its clinical validity.

Hypothesis-free pathway mapping

Profile over 1,000 protein biomarkers for broad proteome coverage and deep profiling of inflammation and disease processes — without any prior biological hypothesis.

Full proteome discovery at biobank scale

The widest multiplexing available — over 5,400 proteins measured with proven specificity from 2 µL of plasma or serum. Validated at Karolinska Institutet for large-scale longitudinal cohorts and translational discovery.

01 — Biological Sample

Just 🩸 1–4 µL of blood plasma or serum — depending on the platform — contains thousands of target proteins for simultaneous measurement. No invasive sampling required.

01

02

03

04

05

06

Olink® PEA is developed by Olink Proteomics AB. Precision Index Discovery is an independent scientific user.

One sample. Seven windows into your biology.

Fertility Index

Proteomic profiling of reproductive endocrinology — quantifying the protein signals governing follicular development, sperm quality, and implantation readiness. For women and men.

Pregnancy Index

Sequential multi-trimester profiling that tracks placental, inflammatory, and metabolic protein dynamics — giving clinicians early signal for gestational complications before symptoms appear.

Organ Index

A protein-level functional scan across nine organ systems — distilled into a single interpretable output that gives clinician and patient a whole-body picture from one appointment.

Vitality Index

Biological age estimated from the proteome using two independent molecular clocks, alongside the specific protein signals accelerating or decelerating the ageing process.

Cancer Index

Liquid biopsy surveillance combining plasma oncoproteomics with circulating-tumour DNA methylation — capturing both the microenvironment signal and the genetic footprint in a single tube.

Metabolomics Index

High-resolution metabolomics by targeted mass spectrometry — mapping energy metabolism, lipid pathways, hormone axes, and micronutrient status from a single blood fraction.

Genomics Index

A permanent genomic reference layer: clinical-grade sequencing for pathogenic variants, drug-metabolism genes, and polygenic risk scores that sharpen every other index over time.

"When a test does not produce a clear answer, the cause is often located in a system that was not initially investigated."

Oncology

Tumour microenvironment profiling, liquid biopsy biomarkers, immunotherapy response characterisation across solid tumours and haematological malignancies.

Immunology & Inflammation

Cytokine and chemokine profiling, immune cell activation, systemic inflammation indices in RA, SLE, IBD, and asthma.

Neurology

CSF and blood-based biomarkers for neurodegeneration, neuroinflammation, Alzheimer's disease, multiple sclerosis, and ALS.

Cardiovascular Disease

Cardiac injury biomarkers, ventricular remodelling, heart failure, and atherosclerosis — enabling risk stratification and treatment monitoring.

Metabolic & Endocrine

Adipokines, hepatokines, insulin signalling proteins, and metabolic stress markers in obesity, T2D, NAFLD, and NASH.

Aging & Longevity

Proteomic hallmarks of biological ageing, frailty, cellular senescence, and the molecular basis of healthy longevity.

Validated by 4,000+
peer-reviewed studies

Selected landmark publications using Olink PEA across clinical and translational research.